Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | BRD4 | O60885 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7823939 | 0.84 | LMNA (0.57) | LMNANPC1RAB9AMEN1KMT2A | |
| SCHEMBL11276300 | 0.83 | LMNA (0.68) | LMNANPC1RAB9AMEN1KMT2A | |
| SCHEMBL7956193 | 0.83 | LMNA (0.56) | LMNANPC1RAB9AMEN1KMT2A | |
| SCHEMBL7050246 | 0.81 | LMNA (0.51) | LMNANPC1RAB9AMEN1KMT2A | |
| SCHEMBL2075491 | 0.80 | LMNA (0.63) | LMNANPC1RAB9AMEN1KMT2A | |
| SCHEMBL6297621 | 0.76 | LMNA (0.49) | LMNANPC1RAB9AMEN1KMT2A | |
| SCHEMBL6696149 | 0.75 | LMNA (0.48) | LMNANPC1RAB9AMEN1KMT2A | |
| SCHEMBL20569876 | 0.75 | ALDH1A1 (0.51) | LMNANPC1RAB9AMEN1KMT2A | |
| SCHEMBL22548401 | 0.74 | BRD4 (0.66) | LMNANPC1RAB9AMEN1KMT2A | |
| SCHEMBL11283064 | 0.73 | LMNA (0.46) | LMNANPC1RAB9AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120004902-A | Heteroaryl heterocycles and uses thereof | 和记黄埔医药（上海）有限公司 | 2025-05-16 | — | — | CN | disclosed |
| CN-119925375-A | Heteroaryl heterocycles and uses thereof | 和记黄埔医药（上海）有限公司 | 2025-05-06 | — | — | CN | disclosed |
| CN-119930630-A | Heteroaryl heterocycles and uses thereof | 和记黄埔医药（上海）有限公司 | 2025-05-06 | — | — | CN | disclosed |
| CN-115151535-B | Heteroaryl heterocycles and uses thereof | 和记黄埔医药（上海）有限公司 | 2025-01-10 | — | — | CN | disclosed |
| US-12173008-B2 | Substituted piperazines as BTK inhibitors | HUTCHISON MEDIPHARMA LIMITED (CN) | 2024-12-24 | — | — | US | disclosed |
| US-20230382916-A1 | HETEROARYL HETEROCYCLIC COMPOUNDS AND USES THEREOF | HUTCHISON MEDIPHARMA LIMITED (CN) | 2023-11-30 | — | — | US | disclosed |
| US-20230382916-A1 | HETEROARYL HETEROCYCLIC COMPOUNDS AND USES THEREOF | HUTCHISON MEDIPHARMA LIMITED (CN) | 2023-11-30 | — | — | US | disclosed |
| US-20230382916-A1 | HETEROARYL HETEROCYCLIC COMPOUNDS AND USES THEREOF | HUTCHISON MEDIPHARMA LIMITED (CN) | 2023-11-30 | — | — | US | disclosed |
| CN-116568687-A | Heteroaryl heterocycles and uses thereof | 和记黄埔医药（上海）有限公司 | 2023-08-08 | — | — | CN | disclosed |
| EP-4214206-A1 | HETEROARYL HETEROCYCLIC COMPOUNDS AND USES THEREOF | Hutchison Medipharma Limited (CN) | 2023-07-26 | — | — | EP | disclosed |
| US-11655254-B2 | Substituted piperazines as BTK inhibitors | HUTCHISON MEDIPHARMA LIMITED (CN) | 2023-05-23 | — | — | US | disclosed |
| US-11655254-B2 | Substituted piperazines as BTK inhibitors | HUTCHISON MEDIPHARMA LIMITED (CN) | 2023-05-23 | — | — | US | disclosed |
| US-11655254-B2 | Substituted piperazines as BTK inhibitors | HUTCHISON MEDIPHARMA LIMITED (CN) | 2023-05-23 | — | — | US | disclosed |
| US-20230043030-A1 | HETEROARYL HETEROCYCLIC COMPOUNDS AND USES THEREOF | HUTCHISON MEDIPHARMA LIMITED (CN) | 2023-02-09 | — | — | US | disclosed |
| EP-4107154-A1 | HETEROARYL HETEROCYCLIC COMPOUNDS AND USES THEREOF | Hutchison Medipharma Limited (CN) | 2022-12-28 | — | — | EP | disclosed |
| US-11478474-B2 | 2-(3′-(hydroxymethyl)-1-methyl-5-((5-(2-methyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-yl)amino)-6-oxo-1,6-dihydro-[3,4′-bipyridin]-2′-yl)-7,7-dimethyl-7,8-dihydro-2H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-1(6H)-one as a BTK inhibitor | HUTCHISON MEDIPHARMA LIMITED (CN) | 2022-10-25 | — | — | US | disclosed |
| US-20220332719-A1 | HETEROARYL HETEROCYCLIC COMPOUNDS AND USES THEREOF | HUTCHISON MEDIPHARMA LIMITED (CN) | 2022-10-20 | — | — | US | disclosed |
| CN-115151535-A | Heteroaryl heterocyclic compounds and uses thereof | 和记黄埔医药（上海）有限公司 | 2022-10-04 | — | — | CN | disclosed |
| US-20220125785-A1 | HETEROARYL HETEROCYCLIC COMPOUNDS AND USES THEREOF | HUTCHISON MEDIPHARMA LIMITED (CN) | 2022-04-28 | — | — | US | disclosed |
| WO-2022057894-A1 | HETEROARYL HETEROCYCLIC COMPOUNDS AND USES THEREOF | HUTCHISON MEDIPHARMA LIMITED (CN) | 2022-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230382916-A1 | HETEROARYL HETEROCYCLIC COMPOUNDS AND USES THEREOF | CYP3A43, CYP3A5, CYP3A7 | LMNA 2463/4885NPC1 244/4885RAB9A 1131/4885 |
| US-20220125785-A1 | HETEROARYL HETEROCYCLIC COMPOUNDS AND USES THEREOF | CYP3A4, CYP4B1, CYP3A5 | LMNA 2581/4885NPC1 244/4885RAB9A 2962/4885 |
| US-12173008-B2 | Substituted piperazines as BTK inhibitors | BTK, SYK, ABL1 | LMNA 4415/4885NPC1 2920/4885RAB9A 2813/4885 |
| US-11478474-B2 | 2-(3′-(hydroxymethyl)-1-methyl-5-((5-(2-methyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-yl)amino)-6-oxo-1,6-dihydro-[3,4′-bipyridin]-2′-yl)-7,7-dimethyl-7,8-dihydro-2H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-1(6H)-one as a BTK inhibitor | BTK, SYK, LCK | LMNA 4252/4885NPC1 4405/4885RAB9A 2713/4885 |
| US-11655254-B2 | Substituted piperazines as BTK inhibitors | BTK, SYK, LYN | LMNA 4235/4885NPC1 3332/4885RAB9A 2733/4885 |
| US-20230043030-A1 | HETEROARYL HETEROCYCLIC COMPOUNDS AND USES THEREOF | CYP3A43, CYP3A5, CYP11B2 | LMNA 1752/4885NPC1 129/4885RAB9A 659/4885 |
| US-20220332719-A1 | HETEROARYL HETEROCYCLIC COMPOUNDS AND USES THEREOF | BTK, SYK, LYN | LMNA 3849/4885NPC1 3334/4885RAB9A 1891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.